Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Phase 1 Completed 17 enrolled Merck Sharp & Dohme LLC Ariad Pharmaceuticals · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the safety, tolerability, and recommended phase 2 dose of oral ridaforolimus administered in combination with intravenous bevacizumab in patients with advanced cancers.

Timeline

Start: 2008-10
Primary completion: 2010-02
Completion: 2010-02

Publications

Results Nemunaitis J, Hochster HS, Lustgarten S, Rhodes R, Ebbinghaus S, Turner CD, Dodion PF, Mita MM. A phase I trial of oral ridaforolimus (AP23573; MK-8669) in combination with bevacizumab for patients with advanced cancers. Clin Oncol (R Coll Radiol). 2013 Jun;25(6):336-42. doi: 10.1016/j.clon.2013.02.005. Epub 2013 Apr 21.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Bevacizumab	Monoclonal antibody	15 mg/kg	Intravenous
Subject	ridaforolimus	Small molecule	30 mg	Oral
Subject	ridaforolimus	Small molecule	40 mg	Oral

Trial of Deforolimus in Combination With Bevacizumab for Patients With Advanced Cancers (8669-010)(COMPLETED)

Summary

Timeline

Publications

Drugs

Indications